What BioMarin Pharmaceutical (BMRN) Investors Need to Know

By Chris Stiles • Monday, March 06 11:53 • Permanent Link

We're taking a closer look at BioMarin Pharmaceutical today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -6.09% compared to 0.54% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions.
BioMarin Pharmaceutical has moved 32.6% over the last year compared to -3.70% for the S&P 500 -- a difference of 36.3%
BMRN has an average analyst rating of buy and is -23.32% away from its mean target price of $123.95 per share
Its trailing 12 month earnings per share (EPS) is $0.76
BioMarin Pharmaceutical has a trailing 12 month Price to Earnings (P/E) ratio of 125.05 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $3.15 and its forward P/E ratio is 30.17
BMRN has a Price to Earnings Growth (PEG) ratio of 0.643, which shows the company is very undervalued compared to its earnings growth estimates.
The company has a Price to Book (P/B) ratio of 4.409 in contrast to the S&P 500's average ratio of 2.95
BioMarin Pharmaceutical is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
BioMarin Pharmaceutical has on average reported free cash flows of $-12,407,400.00 over the last four years, during which time they have grown by an an average of 88.28%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.